AtriCure Beats Growth Bar With 15% Revenue Rise, Raises Full-Year Outlook to $610M
ATRC has more than doubled off its 52-week low of $25.36.
Summary
AtriCure posted Q3 2026 revenue of $154.5 million, up 15.0% year over year, with U.S. revenue up 17.1% to $128.0 million on cryoSPHERE MAX, EnCompass and AtriClip Mini devices. Gross margin expanded 180 basis points to 77.3%, and adjusted EBITDA jumped 51% to $26.8 million. GAAP net income swung to $4.1 million, or $0.08 per share, from a small loss a year ago; adjusted EPS was $0.18 versus a $0.01 loss, and that adjusted EPS of USD 0.18 came in against an IBES estimate of USD -0.05. Management guided full-year 2026 revenue to roughly $606-610 million and adjusted EBITDA to $91-94 million, with adjusted EPS of $0.40-0.46 and continued positive cash generation. The soft spot is minimally invasive ablation, where sales fell as physicians shift to PFA catheters — a competitive headwind worth tracking against the strength in pain management and appendage management. The stock sits near its 52-week high, so the guidance raise is the number that matters for the tape.
At the time of this announcement, ATRC was trading at $60.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $25.36 to $63.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.